Fig 1: Transcription levels of sphingolipid metabolizing enzymes in BV2 microglia. mRNA levels of SPTLC2 (A), CERS2 (B), GALC (C), SPHK2 (D), SMPD1 (E), and SGMS1 (F). Data were shown as the means±SD (n = 6, CON vs Aß, *p < 0.05, **p < 0.01; Aß vs Aß-HLJDD, #p < 0.05, ##p < 0.01).
Fig 2: The levels of sphingolipid metabolizing enzymes in APP/PS1 mice. Representative immunofluorescence results of Aβ (A), CERS2 (B), SPTLC2 (C), SGMS1 (D), and SMPD1 (E) in microglia in hippocampal CA3 region; scale bar, 50 μm. Six random images per section and n=4 mice per group were analyzed. Data were shown as the means±SD (CON vs APP/PS1, **p < 0.01; APP/PS1 vs APP/PS1-HLJDD, ##p < 0.01).
Fig 3: The relationship of CerS2 expression with age at death and CAG repeat length in HD. Relative expression of CerS2 (primary band, ∼40 kDa) to housekeeper expression is used. Pearson’s correlation analyses were used to determine correlations. Plots indicate the line of best fit (solid black line) with 95% confidence intervals (dotted black lines). CerS2 versus age at death in (A) HD caudate (n = 13) and (C) HD putamen (n = 13). CerS2 versus CAG repeat length in (B) HD caudate and (D) HD putamen. Correlation analysis values are provided in Supplementary Tables 30–32. CerS2, ceramide synthase 2; HD, Huntington’s disease.
Fig 4: The expression of CerS1 and CerS2 in Control and HD striatum. The mean expression of CerS1 (~40 kDa) between control and HD subjects adjusted by (B) ß-actin and (D) GAPDH expression in striatal subregions (orange circles for caudate; blue triangles for putamen). The mean expression of CerS2 (~40 kDa) between control and HD subjects adjusted by (F) ß-actin and (H) GAPDH expression in the same regions. Graphs display the mean, standard error of the mean and individual subject values. Representative western blots of CerS1 and CerS2 in the (A and E) caudate and (C and G) putamen with ß-actin and GAPDH housekeepers. ß-Actin was excluded as a housekeeper for putamen samples as the expression was significantly different in HD subjects compared with controls. Samples were combined to create the ‘pool’ and standardize measurements between membranes. Data were assessed for normality using a D’Agostino Pearson Omnibus test and then analysed with an unpaired t-test with Welch’s correction or Mann–Whitney U-test. Accepted significance was set at P < 0.01. Full western blots are provided in Supplementary Figs 7–10. Statistical test information is available in Supplementary Tables 36 and 37. CerS1, ceramide synthase 1; CerS2, ceramide synthase 2; CON, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HD, Huntington’s disease; P, pool.
Supplier Page from Abcam for Anti-CerS2 antibody